Imatinib (INN) is a frontline tyrosine-kinase inhibitor notably used in the targeted therapy of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) by targeting BCR-Abl-expressing leukemic cells. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.